Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878807 | 1.00 | GAA (0.47) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL3617205 | 0.88 | GAA (0.49) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1867619 | 0.88 | GAA (0.49) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1861675 | 0.88 | RAB9A (0.53) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL5593571 | 0.88 | RAB9A (0.53) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1870934 | 0.86 | GAA (0.48) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL970359 | 0.83 | POLB (0.51) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL970360 | 0.83 | POLB (0.51) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1869734 | 0.81 | ALOX5AP (0.47) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1869732 | 0.81 | ALOX5AP (0.47) | GAARAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | GAA 56/4885RAB9A 420/4885ALDH1A1 1084/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | GAA 25/4885RAB9A 466/4885ALDH1A1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.